blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2165708

EP2165708 - New pyrazole derivatives as transforming growth factor (TGF) inhibitors [Right-click to bookmark this link]
Former [2010/12]NEW PYRAZOLE DERIVATIVES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS
[2010/30]
StatusThe application is deemed to be withdrawn
Status updated on  22.07.2011
Database last updated on 20.09.2024
Most recent event   Tooltip22.07.2011Application deemed to be withdrawnpublished on 24.08.2011  [2011/34]
Applicant(s)For all designated states
Pfizer Products Inc.
Eastern Point Road
Groton, CT 06340 / US
[2010/12]
Inventor(s)01 / MUNCHHOF, Michael John
Pfizer Global Research & Development Eastern Point Road
GROTON, CT CT06340 / US
02 / BLUMBERG, Laura Cook
Pfizer Global Research & Development Eastern Point Road
GROTON, CT CT06340 / US
 [2010/12]
Representative(s)Brunetti, Fabrizio
Pfizer Limited
European Patent Department
Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
[N/P]
Former [2010/12]Brunetti, Fabrizio
Pfizer Limited European Patent Department Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
Application number, filing date09177298.808.09.2003
[2010/12]
Priority number, dateUS20020412146P18.09.2002         Original published format: US 412146 P
US20030484543P02.07.2003         Original published format: US 484543 P
[2010/12]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2165708
Date:24.03.2010
Language:EN
[2010/12]
Type: A3 Search report 
No.:EP2165708
Date:28.07.2010
[2010/30]
Search report(s)(Supplementary) European search report - dispatched on:EP28.06.2010
ClassificationIPC:A61K31/4439, C07D401/14, C07D413/14, C07D471/04, A61P35/00
[2010/30]
CPC:
C07D471/04 (EP,KR,US); C07D401/14 (EP,KR,US); A61P1/16 (EP);
A61P11/00 (EP); A61P13/12 (EP); A61P17/00 (EP);
A61P17/02 (EP); A61P3/10 (EP); A61P35/00 (EP);
A61P43/00 (EP); A61P5/00 (EP); A61P9/00 (EP);
A61P9/10 (EP); C07D405/14 (EP,US); C07D413/14 (KR) (-)
Former IPC [2010/12]A61K31/4439, C07D401/14, C07D405/14, C07D471/04, A61P35/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2010/12]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:Neue Pyrazol-Verbindungen als Hemmer des transformierenden Wachstumsfaktors (TGF)[2010/30]
English:New pyrazole derivatives as transforming growth factor (TGF) inhibitors[2010/30]
French:Nouveaux composés de pyrazole utilisés comme inhibiteurs du facteur de croissance transformant (TGF)[2010/30]
Former [2010/12]NEUE PYRAZOL-VERBINDUNGEN ALS HEMMER DES TRANSFORMIERENDEN WACHSTUMSFAKTORS (TGF)
Former [2010/12]NEW PYRAZOLE DERIVATIVES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS
Former [2010/12]NOUVEAUX COMPOSÉS DE PYRAZOLE UTILISÉS COMME INHIBITEURS DU FACTEUR DE CROISSANCE TRANSFORMANT (TGF)
Examination procedure15.02.2011Application deemed to be withdrawn, date of legal effect  [2011/34]
16.03.2011Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time  [2011/34]
Parent application(s)   TooltipEP03797443.3  / EP1542684
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20030797443) is  09.09.2005
Fees paidRenewal fee
29.03.2010Renewal fee patent year 03
29.03.2010Renewal fee patent year 04
29.03.2010Renewal fee patent year 05
29.03.2010Renewal fee patent year 06
29.03.2010Renewal fee patent year 07
30.09.2010Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]EP0388691  (STERLING DRUG INC [US]) [X] 1-10 * see scheme A *;
 [X]WO02062794  (GLAXO GROUP LTD [GB], et al) [X] 1-12 * claims 1,10 *;
 [X]WO02062787  (GLAXO GROUP LTD [GB], et al) [X] 1-12 * claims 1,12 *;
 [X]WO02066462  (GLAXO GROUP LTD [GB], et al) [X] 1-12 * claims 1,10 *;
 [XP]WO02088107  (EISAI CO LTD [JP], et al) [XP] 1-12 * see abstract and examples (e.g. compounds 181, 361) *;
 [X]  - CROSSFIRE BEILSTEIN, Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE, (19740101), Database accession no. 1220267, XP002262347 [X] 1-10 * abstract *
 [X]  - CROSSFIRE BEILSTEIN, Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE, (19740101), Database accession no. 1181440, XP002262348 [X] 1-10 * abstract *
 [X]  - CAPLUS, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (19910803), Database accession no. 119:72619, URL: STN, XP002262349 [X] 1-10 * abstract *
 [X]  - CAPLUS, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (20000601), Database accession no. 134:29414, URL: STN, XP002262350 [X] 1-10 * abstract *
 [X]  - CAPLUS, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (19941228), Database accession no. 125:247806, URL: STN, XP002262351 [X] 1-10 * abstract *
by applicantUS3119742
 US3492397
 US3538214
 US4060598
 US4173626
 WO0031063
 WO0240476
 WO02072576
    - DAVIES, 1. W. ET AL., J. ORG. CHEM., (2000), vol. 65, pages 8415 - 8420
    - MORAN, D. B.; MORTON, G. O.; ALBRIGHT, J. D., J. HETEROCYCL. CHEM., (1986), vol. 23, pages 1071 - 1077
    - BUNDGARD, Design of Prodrugs, ELSEVIER, (1985), pages 7 - 9
    - SILVERMAN, Organic Chemistry of Drug Design and Drug Action, ACADEMIC PRESS, (1992), pages 352 - 401
    - LAPING, N.J. ET AL., MOLECULAR PHARMACOLOGY, (2002), vol. 62, pages 58 - 64
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.